XORTX adds exhibits into Form F-3 (333-269429) via 6-K

Rhea-AI Filing Summary

XORTX Therapeutics Inc. filed a Form 6-K furnishing transaction-related exhibits and incorporating them by reference into its Form F-3 registration statement (File No. 333-269429), as amended and supplemented.

The exhibits include a press release dated October 21, 2025, a Placement Agency Agreement with D. Boral Capital LLC, a form of Securities Purchase Agreement, a form of Lock-Up Agreement, and a form of Pre-Funded Common Share Purchase Warrant. The report was signed by President and CEO Allen Davidoff on October 22, 2025.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 6-K: How Foreign Companies Report to the SEC →

Accepted by SEC EDGAR 10/22/2025 - 09:24 PM Learn about SEC filing dates

FAQ

What did XRTX file in this update?

XORTX filed a Form 6-K furnishing exhibits related to a financing, including agreements and a press release.

Which exhibits are included with XRTX’s 6-K?

A press release (Oct 21, 2025), a Placement Agency Agreement with D. Boral Capital LLC, a form of Securities Purchase Agreement, a form of Lock-Up Agreement, and a form of Pre-Funded Common Share Purchase Warrant.

Are these exhibits incorporated into a registration statement?

Yes. Exhibits 99.2, 99.3, 99.4 and 99.5 are incorporated by reference into XORTX’s Form F-3 (File No. 333-269429), as amended and supplemented.

Who signed the filing for XRTX and when?

President and Chief Executive Officer Allen Davidoff signed the report on October 22, 2025.

What type of warrant is referenced in the exhibits?

A form of Pre-Funded Common Share Purchase Warrant is included.

Which placement agent is named in the exhibits?

D. Boral Capital LLC is named in the Placement Agency Agreement.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of October 2025

Commission File Number:  001-40858

XORTX THERAPEUTICS INC.

(Translation of registrant’s name into English)

3710 – 33^rd Street NW

Calgary, Alberta T2L 2M1

Canada

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

x   Form 20-F                      ¨   Form 40-F  

INCORPORATION BY REFERENCE

Exhibits 99.2, 99.3, 99.4 and 99.5 to this report on Form 6-K are hereby incorporated by reference as an Exhibit to the Registration Statement on Form F-3 of XORTX Therapeutics Inc. (File No. 333-269429), as amended and supplemented.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

XORTX Therapeutics Inc.

(Registrant)

Date:  October 22, 2025	By:	/s/ Allen Davidoff
		Name:    Allen Davidoff
		Title:      President and Chief Executive Officer

Form 6-K Exhibit Index

Exhibit  Number		Document Description
99.1		Press Release of the Registrant, dated October 21, 2025
99.2		Placement Agency Agreement between D. Boral Capital LLC and XORTX Therapeutics Inc., dated October 21, 2025
99.3		Form of Securities Purchase Agreement, between XORTX Therapeutics Inc. and Purchaser, dated October 21, 2025
99.4		Form of Lock-Up Agreement
99.5		Form of Pre-Funded Common Share Purchase Warrant